Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydroxypropyl betadex - Cyclo Therapeutics

Next Previous
Drug Profile

Hydroxypropyl betadex - Cyclo Therapeutics

Alternative Names: HP-Beta-CD - Cyclo Therapeutics; HP-β-CD - Cyclo Therapeutics; Hydroxypropyl-beta-cyclodextrin - Cyclo Therapeutics; Trappsol Cyclo; Trappsol® Hydroxypropyl Beta Cyclodextrin-Endotoxin Controlled (THPB-EC) grade - Cyclo Therapeutics

Latest Information Update: 09 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CTD Holdings
  • Developer Cyclo Therapeutics
  • Class Anti-inflammatories; Antidementias; Antivirals; Beta-Cyclodextrins; Ethers; Peripheral vasodilators; Urologics; Vascular disorder therapies
  • Mechanism of Action Binding agents; Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Niemann-Pick disease type C
  • New Molecular Entity No

Highest Development Phases

  • Phase III Niemann-Pick disease type C
  • Phase II Alzheimer's disease
  • No development reported Diabetic nephropathies; Peripheral arterial disorders; Viral infections

Most Recent Events

  • 09 Sep 2024 Cyclo Therapeutics completed a phase III TransportNPC trial in Niemann-Pick disease type C (In adolescents, In children, In adults, In the elderly) in Argentina, Australia, Brazil, Germany, Israel, Italy, Poland, Saudi Arabia, Spain, Taiwan, Turkey, United Kingdom, USA (IV) (NCT04860960)
  • 05 Sep 2024 Adverse events data from a phase III clinical trials in Niemann-Pick disease type C released by Cyclo Therapeutics
  • 15 Aug 2024 Cyclo Therapeutics receives patent allowance for Hydroxypropyl betadex in the European Union

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top